Literature DB >> 22358655

Effects of endotoxin on proliferation of human hematopoietic cell precursors.

J J Rinehart1, L Keville.   

Abstract

In examining the effects of corticosteroids on hematopoiesis in vitro, we observed that results were highly dependent on the lot of commercial fetal calf serum (FCS) utilized. We hypothesized that this variability correlated with the picogram (pg) level of endotoxin contaminating the FCS. Randomly obtained commercial lots of FCS contained 0.39 to 187 pg/ml of lipopolysaccharide (LPS). Standard FCS concentrations in hematopoietic precursor proliferation assays (granulocyte-marcrophage colony forming units [CFU-GM]) resulted in final LPS levels as high as 40 pg/ml. LPS (2-5 pg/ml) added to essentially endotoxin-free cultures, induced human mononuclear cell release of interleukin (IL)-1, IL-6 and granulocyte colony stimulating factor (G-CSF). Lots of FCS induced the release of IL-1, IL-6, and G-CSF from human mononuclear cells and the release of these factors correlated with the level of contaminating LPS. Human bone marrow CFU-GM proliferation, in response to granulocyte-macrophage colony stimulating factor (GM-CSF), positively correlated with the level of LPS contaminating the FCS and the FCS-induced release of IL-6 from mononuclear cells. CFU-GM proliferation of human bone marrow cluster of differentiation (CD) 34+CD14-cells were not affected by the presence of endotoxin. These data suggest that LPS at 2-5 pg/ml may induce bone marrow accessory cell release of hematopoietic growth factors, thus altering proliferative response of hematopoietic precursors and confounding the study of exogenously added cytokines to culture systems.

Entities:  

Year:  1997        PMID: 22358655      PMCID: PMC3449581          DOI: 10.1023/A:1007904122406

Source DB:  PubMed          Journal:  Cytotechnology        ISSN: 0920-9069            Impact factor:   2.058


  9 in total

Review 1.  Gram-negative endotoxin: an extraordinary lipid with profound effects on eukaryotic signal transduction.

Authors:  C R Raetz; R J Ulevitch; S D Wright; C H Sibley; A Ding; C F Nathan
Journal:  FASEB J       Date:  1991-09       Impact factor: 5.191

Review 2.  Lipopolysaccharide-binding protein and CD14 in the lipopolysaccharide-dependent activation of cells.

Authors:  P S Tobias; R J Ulevitch
Journal:  Chest       Date:  1994-03       Impact factor: 9.410

Review 3.  NF-kappa B and rel proteins in innate immunity.

Authors:  E B Kopp; S Ghosh
Journal:  Adv Immunol       Date:  1995       Impact factor: 3.543

4.  Treatment of cancer patients with endotoxin induces release of endogenous cytokines.

Authors:  A Mackensen; C Galanos; R Engelhardt
Journal:  Pathobiology       Date:  1991       Impact factor: 4.342

5.  Independent regulation of M-CSF and G-CSF gene expression in human monocytes.

Authors:  E Vellenga; A Rambaldi; T J Ernst; D Ostapovicz; J D Griffin
Journal:  Blood       Date:  1988-06       Impact factor: 22.113

6.  Direct stimulation of cytokines (IL-1 beta, TNF-alpha, IL-6, IL-2, IFN-gamma and GM-CSF) in whole blood. I. Comparison with isolated PBMC stimulation.

Authors:  D De Groote; P F Zangerle; Y Gevaert; M F Fassotte; Y Beguin; F Noizat-Pirenne; J Pirenne; R Gathy; M Lopez; I Dehart
Journal:  Cytokine       Date:  1992-05       Impact factor: 3.861

7.  Two types of septic shock classified by the plasma levels of cytokines and endotoxin.

Authors:  S Endo; K Inada; Y Inoue; Y Kuwata; M Suzuki; H Yamashita; S Hoshi; M Yoshida
Journal:  Circ Shock       Date:  1992-12

8.  Corticosteroid modulation of interleukin-1 hematopoietic effects and toxicity in a murine system.

Authors:  J Rinehart; E W Delamater; L Keville; J Measel
Journal:  Blood       Date:  1994-09-01       Impact factor: 22.113

9.  Increased circulating cytokines, cytokine antagonists, and E-selectin after intravenous administration of endotoxin in humans.

Authors:  D B Kuhns; W G Alvord; J I Gallin
Journal:  J Infect Dis       Date:  1995-01       Impact factor: 5.226

  9 in total
  1 in total

Review 1.  Immunotoxicity Considerations for Next Generation Cancer Nanomedicines.

Authors:  Gary Hannon; Joanne Lysaght; Neill J Liptrott; Adriele Prina-Mello
Journal:  Adv Sci (Weinh)       Date:  2019-08-01       Impact factor: 16.806

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.